CONTENTS:
- Better data, better policy and better lives: a call for improved drug monitoring and concerted responses [Editorial]. Comiskey C., Bretteville-Jensen A.L., Bergeron H., Buhringer G., Dargan P., Davoli M., et al., p. 199-200.
- Dropout rates of in-person psychosocial substance use disorder treatments: a systematic review and meta-analysis. Lappan S.N., Brown A.W., Hendricks P.S., p. 201-217.
- Contextual characteristics of adults' drinking occasions and their association with levels of alcohol consumption and acute alcohol-related harm: a mapping review. Stevely A.K., Holmes J., Meier P.S., p. 218-229.
- The decline in youth drinking in England - is everyone drinking less? A quantile regression analysis. Oldham M., Callinan S., Whitaker V., Fairbrother H., Curtis P., Meier P., et al., p. 230-238.
- Opioid use and dropout from extended-release naltrexone in a controlled trial: implications for mechanism. Nunes E.V., Bisaga A., Krupitsky E., Nangia N., Silverman B.L., Akerman S.C., et al., p. 239-246.
- Commentary on Nunes et al. (2020): Blocked opioid use in antagonist treatment-time for cognitive and user-centered perspectives. Kunoe N., p. 247-248.
- Comparison of psychiatric comorbidity in treatment-seeking, opioid-dependent patients with versus without chronic pain. Higgins C., Smith B.H., Matthews K., p. 249-258.
- Commentary on Higgins et al. (2020): How are chronic pain, psychological distress and opioid dependence related? Sullivan M.D., p. 259-260.
- Recent trends in heroin and pharmaceutical opioid-related harms in Victoria, Australia up to 2018. Lam T., Kuhn L., Hayman J., Middleton M., Wilson J., Scott D., et al., p. 261-269.
- The Psychoactive Surveillance Consortium and Analysis Network (PSCAN): the first year. Monte A.A., Hopkinson A., Saben J., Shelton S.K., Thornton S., Schneir A., et al., p. 270-278.
- Life-course trajectories of cannabis use: a latent class analysis of a New Zealand birth cohort. Boden J.M., Dhakal B., Foulds J.A., Horwood L.J., p. 279-290.
- Maternal and infant characteristics associated with maternal opioid overdose in the year following delivery. Nielsen T., Bernson D., Terplan M., Wakeman S.E., Yule A.M., Mehta P.K., et al., p. 291-301.
- Assessment of the Choice Behavior Under Cued Conditions (CBUCC) paradigm as a measure of motivation to smoke under laboratory conditions. Gass J.C., Tiffany S.T., p. 302-312.
- Commentary on Gass & Tiffany (2020): Laboratory and real-world research-a productive tension. Shiffman S., p. 313-314.
- Population-level predictors of changes in success rates of smoking quit attempts in England: a time series analysis. Beard E., Jackson S.E., West R., Kuipers M.A.G., Brown J., p. 315-325.
- Association of parental substance use disorder with offspring cognition: a population family-based study. Khemiri L., Larsson H., Kuja-Halkola R., D'Onofrio B.M., Lichtenstein P., Jayaram-Lindstrom N., et al., p. 326-336.
- Sibling comparisons elucidate the associations between educational attainment polygenic scores and alcohol, nicotine and cannabis. Salvatore J.E., Barr P.B., Stephenson M., Aliev F., Kuo S.I., Su J., et al., p. 337-346.
- Increases in methamphetamine use among heroin treatment admissions in the United States, 2008-17. Jones C.M., Underwood N., Compton W.M., p. 347-353.
- Factor structure, internal reliability and construct validity of the Methadone Maintenance Treatment Stigma Mechanisms Scale (MMT-SMS). Smith L.R., Mittal M.L., Wagner K., Copenhaver M.M., Cunningham C.O., Earnshaw V.A., p. 354-367.
- Measuring fidelity to behavioural support delivery for smoking cessation and its association with outcomes. Dogar O., Boehnke J.R., Lorencatto F., Sheldon T.A., Siddiqi K., p. 368-380.
- Addiction Lives: Dennis McCarty. Berridge V., p. 381-383.
- Response to Darke et al. (2019): Circumstances of death of opioid users being treated with naltrexone. Streel E., Brewer C., p. 384.
- Taiwanese drink driving. Tunbridge R., p. 384-385.